- Home
- MLYS vs VEL Comparison
MLYS vs VEL Comparison
Compare MLYS & VEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- VEL
- Stock Information
- Founded
- MLYS 2019
- VEL 2004
- Country
- MLYS United States
- VEL United States
- Employees
- MLYS N/A
- VEL N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- VEL Finance: Consumer Services
- Sector
- MLYS Health Care
- VEL Finance
- Exchange
- MLYS Nasdaq
- VEL Nasdaq
- Market Cap
- MLYS 590.3M
- VEL 660.6M
- IPO Year
- MLYS 2023
- VEL 2020
- Fundamental
- Price
- MLYS $11.87
- VEL $20.32
- Analyst Decision
- MLYS Strong Buy
- VEL Buy
- Analyst Count
- MLYS 2
- VEL 5
- Target Price
- MLYS $30.00
- VEL $20.80
- AVG Volume (30 Days)
- MLYS 255.3K
- VEL 40.7K
- Earning Date
- MLYS 11-11-2024
- VEL 11-07-2024
- Dividend Yield
- MLYS N/A
- VEL N/A
- EPS Growth
- MLYS N/A
- VEL 45.05
- EPS
- MLYS N/A
- VEL 1.84
- Revenue
- MLYS N/A
- VEL $161,829,000.00
- Revenue This Year
- MLYS N/A
- VEL N/A
- Revenue Next Year
- MLYS N/A
- VEL $11.05
- P/E Ratio
- MLYS N/A
- VEL $11.06
- Revenue Growth
- MLYS N/A
- VEL 35.27
- 52 Week Low
- MLYS $6.06
- VEL $13.54
- 52 Week High
- MLYS $16.91
- VEL $20.51
- Technical
- Relative Strength Index (RSI)
- MLYS 41.32
- VEL 65.82
- Support Level
- MLYS $11.30
- VEL $19.84
- Resistance Level
- MLYS $13.06
- VEL $20.25
- Average True Range (ATR)
- MLYS 1.01
- VEL 0.27
- MACD
- MLYS -0.22
- VEL 0.06
- Stochastic Oscillator
- MLYS 14.43
- VEL 86.90
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.